Neurokinin B acts via the neurokinin-3 receptor in the retrochiasmatic area to stimulate luteinizing hormone secretion in sheep.
Recent data have demonstrated that mutations in the receptor for neurokinin B (NKB), the NK-3 receptor (NK3R), produce hypogonadotropic hypogonadism in humans. These data, together with reports that NKB expression increases after ovariectomy and in postmenopausal women, have led to the hypothesis that this tachykinin is an important stimulator of GnRH secretion. However, the NK3R agonist, senktide, inhibited LH secretion in rats and mice. In this study, we report that senktide stimulates LH secretion in ewes. A dramatic increase in LH concentrations to levels close to those observed during the preovulatory LH surge was observed after injection of 1 nmol senktide into the third ventricle during the follicular, but not in the luteal, phase. Similar increases in LH secretion occurred after insertion of microimplants containing this agonist into the retrochiasmatic area (RCh) in anestrous or follicular phase ewes. A low-dose microinjection (3 pmol) of senktide into the RCh produced a smaller but significant increase in LH concentrations in anestrous ewes. Moreover, NK3R immunoreactivity was clearly evident in the RCh, although it was not found in A15 dopaminergic cell bodies in this region. These data provide evidence that NKB stimulates LH (and presumably GnRH) secretion in ewes and point to the RCh as one important site of action. Based on these data, and the effects of NK3R mutations in humans, we hypothesize that NKB plays an important stimulatory role in the control of GnRH and LH secretion in nonrodent species.
Billings
Heather J
HJ
Department of Neurobiology and Anatomy, West Virginia University, Health Sciences Center, Morgantown, West Virginia 26506-9128, USA. hbillings@hsc.wvu.edu
Connors
John M
JM
Altman
Stephanie N
SN
Hileman
Stanley M
SM
Holaskova
Ida
I
Lehman
Michael N
MN
McManus
Christina J
CJ
Nestor
Casey C
CC
Jacobs
Britni H
BH
Goodman
Robert L
RL
D000780:Anestrus / Q000097:blood / Q000187:drug effects; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005260:Female; D005498:Follicular Phase / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D007987:Gonadotropin-Releasing Hormone / Q000097:blood / Q000378:metabolism; D007276:Injections, Intraventricular; D008183:Luteal Phase / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D008954:Models, Biological; D015287:Neurokinin B / Q000494:pharmacology* / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D018042:Receptors, Neurokinin-3 / Q000819:agonists / Q000378:metabolism / Q000502:physiology*; D012756:Sheep; D013373:Substance P / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology
D018377:Neurotransmitter Agents; D010446:Peptide Fragments; D018042:Receptors, Neurokinin-3; C054724:senktide; D013373:Substance P; D007987:Gonadotropin-Releasing Hormone; D015287:Neurokinin B; D007986:Luteinizing Hormone; D004298:Dopamine